Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Operating expenses:
Research and development	$ 16,610	$ 19,089	$ 43,225	$ 38,396
General and administrative	29,201	10,657	46,801	20,443
Total operating expenses	45,811	29,746	90,026	58,839
Operating loss	(45,811)	(29,746)	(90,026)	(58,839)
Other income:
Interest income	1,357	776	3,050	1,699
Foreign currency exchange gain (loss)	67	(1,299)	581	(843)
Other income	2,119	2,619	3,685	5,016
Total other income	3,543	2,096	7,316	5,872
Net loss	(42,268)	(27,650)	(82,710)	(52,967)
Other comprehensive (loss) income:
Foreign currency translation gain (loss)	166	(419)	38	(328)
Unrealized holding gain on marketable securities	651	440	1,715	832
Reclassification adjustment for realized (gain) on marketable securities included in net loss	(649)	(595)	(966)	(909)
Other comprehensive income (loss)	168	(574)	787	(405)
Comprehensive loss	$ (42,100)	$ (28,224)	$ (81,923)	$ (53,372)
Net loss per share to common stockholders, basic	$ (0.91)	$ (0.8)	$ (1.78)	$ (1.54)
Net loss per share to common stockholders, diluted	$ (0.91)	$ (0.8)	$ (1.78)	$ (1.54)
Weighted average common shares outstanding, basic	46,695,220	34,565,955	46,464,099	34,490,090
Weighted average common shares outstanding, diluted	46,695,220	34,565,955	46,464,099	34,490,090